🍎 🍕 Less apples, more pizza 🤔 Have you seen Buffett’s portfolio recently?Explore for Free

Guggenheim bullish on Keros Therapeutics stock driven by PAH treatment prospects

EditorEmilio Ghigini
Published 09/23/2024, 03:53 AM
KROS
-


On Monday, Keros Therapeutics, Inc. (NASDAQ:KROS) stock received a Buy rating from Guggenheim, with a price target set at $96. The clinical-stage biotechnology company, known for its work on the growth factor-beta (TGF-β) superfamily signaling pathway, has garnered attention for its potential in treating a range of diseases.

The company's CEO, Jasbir Seehra, brings significant expertise from his time at Acceleron, contributing to the development of successful treatments such as sotatercept and luspatercept.

Guggenheim's positive outlook on Keros is largely due to the company's promising drug candidates, particularly in the field of hematology. The analyst highlighted elritercept, which is being investigated for the treatment of myelodysplastic syndromes and myelofibrosis, as commercially viable programs. These conditions are characterized by an imbalance in TGF-β pathway signaling, which Keros's treatments aim to correct.

The firm's bullish stance is further reinforced by the prospects of another Keros drug candidate, cibotercept, for the treatment of pulmonary arterial hypertension (PAH). The analyst's expectations for this particular treatment play a key role in the positive rating and high price target for the company's stock.

Keros Therapeutics focuses on developing a pipeline of drug candidates for diseases that involve an imbalance in the TGF-β pathway. This includes not only myelodysplastic syndromes and myelofibrosis but also extends to other serious conditions such as PAH, obesity, and more.

The company's strategic approach leverages the extensive experience of its CEO in TGF-β superfamily ligand trap drug development. This expertise is expected to drive the success of Keros's hematology programs and contribute to the company's growth in the biotechnology sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.